Physician

Mitchell B Alden, D.O.

According to 2025 Medicare claims, Mitchell Alden, D.O. (NPI: 1861474991) practices hematology/oncology in the Montgomery County-Bucks County-Chester County, PA market, with the plurality of this provider's patient population coming from Bucks, PA. This provider's primary affiliated billing organization is ALLIANCE CANCER SPECIALISTS P.C. (NPI: 1487923686; TIN: 452552343) and primary practice location at 18901-2554.

Alden's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 791 traditional Medicare patients, billed 266,668 HCPCS/CPT codes, and received $4,714,365 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,232 prescription claims across 276 beneficiaries totaling $2,933,422 in drug costs, led by Lenalidomide (Lenalidomide). 2020 DME data shows 38 claims. Open Payments data shows 149 records totaling $3,798. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,602,541 to $4,714,365. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,100,351 to $2,933,422. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	764	176,230	$2,602,541
2016	728	222,307	$2,915,513
2017	766	185,183	$3,003,490
2018	740	265,842	$4,004,110
2019	763	234,307	$3,745,110
2020	709	326,615	$4,674,874
2021	695	298,562	$5,169,095
2022	673	314,807	$4,270,172
2023	712	286,571	$4,200,598
2024	791	266,668	$4,714,365

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	214	1,241	$1,100,351
2016	210	1,233	$1,247,593
2017	196	918	$1,048,534
2018	201	892	$1,789,511
2019	211	1,084	$2,666,889
2020	241	1,298	$3,441,101
2021	234	1,254	$2,848,002
2022	228	1,137	$2,221,915
2023	233	1,103	$1,941,845
2024	276	1,232	$2,933,422

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	87	$6,106
2016	N/R	44	$2,346
2017	N/R	24	$763
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	38	$3,786
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	211	467	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	373	590	$73
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	270	448	$14
96375	Injection of additional new drug or substance into vein	120	757	$13
96372	Injection of drug or substance under skin or into muscle	111	541	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	33	917	$474,657
Erleada	Apalutamide	31	960	$441,240
Pomalyst	Pomalidomide	18	504	$320,245
Calquence	Acalabrutinib Maleate	21	630	$282,084
Tagrisso	Osimertinib Mesylate	15	450	$255,549

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	149	$3,798	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mitchell B. Alden, D.O.?

Tedicare shows public-source Medicare data for Mitchell B. Alden, D.O. (NPI 1861474991), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mitchell B. Alden, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mitchell B. Alden, D.O.?

Mitchell B. Alden, D.O. is linked to ALLIANCE CANCER SPECIALISTS P.C. (billing NPI 1487923686) in the available physician profile data.

Does Mitchell B. Alden, D.O. have Open Payments data?

Mitchell B. Alden, D.O. has 149 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.